Journal: Cell Communication and Signaling : CCS

Article Title: Pharmacologic targeting of the P-TEFb complex as a therapeutic strategy for chronic myeloid leukemia

doi: 10.1186/s12964-021-00764-5

Figure Lengend Snippet: P-TEFb was involved in wogonin-induced erythroid differentiation and regulated the protein interaction of GATA-1, RUNX1 and FOG-1. a After treatment with wogonin (0, 5, 10, 20, 40 and 80 μM) for 48 h in K562 and KU-812 cells, and in #1 primary CML cells wogonin (0, 20, 40, 80 μM) was treated for 48 h. Protein expression levels of p-RNA Pol II (Ser2), p-RNA Pol II (Ser5), RNA Pol II and CDK9 were analyzed by western blot. β-actin was used as a loading control. The results are representative of three independent experiments(mean ± SD). * p < 0.05, ** p < 0.01, *** p < 0.001, compared with control group. b After treatment with wogonin (0, 5, 10, 20, 40 and 80 μM) for 48 h in K562 and KU-812 cells, and in #1 primary CML cells wogonin (0, 20, 40, 80 μM) was treated for 48 h. Protein expression levels of Cyclin T1 were analyzed by western blot. β-actin was used as a loading control. The results are representative of three independent experiments. (mean ± SD). * p < 0.05, ** p < 0.01, compared with control group. c KU-812 cells were treated with wogonin (0, 5, 10 and 20 μM) for 72 h. Cells were immunoprecipitated with anti-GATA-1 antibody, followed by western blot analysis with anti-FOG-1 and anti-RUNX1 antibodies. GAPDH and β-actin were used as a loading control respectively. The results are representative of three independent experiments (mean ± SD). * p < 0.05, ** p < 0.01, compared with control group

Article Snippet: Primary antibodies specific for RNA Pol II, p-RNA Pol II -Ser2, p-RNA Pol II -Ser5, MCL-1, Cyclin T1, FOG-1, GAPDH and β-actin were obtained from ABclonal Technology (Wuhan, China).

Techniques: Expressing, Western Blot, Control, Immunoprecipitation

Journal: Cell Communication and Signaling : CCS

Article Title: Pharmacologic targeting of the P-TEFb complex as a therapeutic strategy for chronic myeloid leukemia

doi: 10.1186/s12964-021-00764-5

Figure Lengend Snippet: Wogonin modulated P-TEFb kinase activity in vivo . a The protein expression of p-RNA Pol II (Ser2), p-RNA Pol II (Ser5), CyclinT1, CDK9 and MCL-1 in KU-812 xenografts. β-actin was used as a loading control. The results are representative of three independent experiments (mean ± SD). * p < 0.05, ** p < 0.01, compared with control group. b Immunofluorescence and stained with p-RNA Pol II (Ser2) (green fluorescence), p-RNA Pol II (Ser5) (green fluorescence) and MCL-1 (green fluorescence) respectively, as well as DAPI (blue fluorescence) in tumor of KU-812-bearing NOD/SCID mice. They were detected by confocal microscopy (FV1000; Olympus) with FV10-ASW2.1 acquisition software (Olympus) at room temperature (Original magnification × 600). c The expression of CD71 and GPA was detected in tumor of KU-812-bearing NOD/SCID mice by flow cytometry analyses. d Quantification of the expression of CD71/GPA. Data represent mean ± SD of three independent experiments. *** p < 0.001, compared with control group

Article Snippet: Primary antibodies specific for RNA Pol II, p-RNA Pol II -Ser2, p-RNA Pol II -Ser5, MCL-1, Cyclin T1, FOG-1, GAPDH and β-actin were obtained from ABclonal Technology (Wuhan, China).

Techniques: Activity Assay, In Vivo, Expressing, Control, Immunofluorescence, Staining, Fluorescence, Confocal Microscopy, Software, Flow Cytometry

Journal: Disease Models & Mechanisms

Article Title: The infantile myofibromatosis NOTCH3 L1519P mutation leads to hyperactivated ligand-independent Notch signaling and increased PDGFRB expression

doi: 10.1242/dmm.046300

Figure Lengend Snippet: NOTCH3 L1519P produces ICD in a ligand-independent manner. (A) Western blot analysis of FL, TMIC and NEXT and ICD fragments from cell extracts using an anti-NOTCH3 ICD antibody, following activation of the cells by immobilized jagged2 (Jag2-Fc) and treatment with the γ-secretase inhibitor DAPT or MG132, as indicated. (B) NIH3T3 cells were transfected with wild-type, NOTCH3 L1519P or control plasmid together with 12XCSL-luc reporter and β-gal plasmids and cultured on immobilized jagged2 (Jag2) in combination with treatment by DMSO or DAPT, as indicated ( n =3). Statistical analysis was performed from three experiments using paired Student's t -test, * P <0.1, ** P <10 −2 , *** P <10 −3 , RLU, relative luminescence units.

Article Snippet: Cell culture plates were coated with recombinant human jagged2 Fc chimeric protein (#P78504, R&D Systems) at 0.5 μg/ml, with IgG Fc fragment as control.

Techniques: Western Blot, Activation Assay, Transfection, Control, Plasmid Preparation, Cell Culture

Journal: Cell Death & Disease

Article Title: Ovarian tumor cell-derived JAGGED2 promotes omental metastasis through stimulating the Notch signaling pathway in the mesothelial cells

doi: 10.1038/s41419-024-06512-0

Figure Lengend Snippet: A Schematic diagram of SKOV3-ip cell injection in mouse peritoneum. B Locations of (i) ascites, (ii) omentum, (iii) primary ovary, and (iv) diaphragm tumor progression 3- weeks after i.p. injection (left panel). H & E staining of omentum without (top right panel) and with tumor (right bottom panel). C Endpoint analysis of malignant ascites and total number of tumor nodules in omentectomized mice 4 weeks after intraperitoneal cell injection of SKOV3-ip cells. Data are shown as Mean +/-SEM ( n = 3). Statistical significance was calculated using Kruskal-Wallis one-way ANOVA followed by Dunn’s multiple comparison test. ** P < 0.01, **** P < 0.0001. D–F Jagged2 protein and RNA expression in whole mouse omentum three weeks following in vivo i.p. injection of SKOV3-ip tumor cells. Immunofluorescence ( D ), Immunoblot ( E ), and qRT-PCR (F) analysis were performed using Jagged2 specific antibody and probe (** P < 0.01; Scale bars 100 μm). G Diagram of the mesothelium in 3D culture. Primary human omental fibroblasts are plated with human omental ECM and cultured for 6 hours. The fibroblasts are overlaid with human omental mesothelial cells and cultured for an additional 24 hours before OvCa cells are seeded. The purpose of the use of the 3D culture system was to investigate OvCa cells’ adhesion, invasion, and proliferation. H Ex-vivo human omentum adhesion, invasion, and proliferation assay with PHK25 labeled OvCa cells and the schematic of cell sorting by FACS. I Western blot analysis of Jagged2 protein in the surface cells of the human omentum in two culture conditions. Cells were cultured in human omentum without fluorescently labeled cells (unattached) or PHK25 labeled SKOV3-ip cells (attached) after FACS sorting. J qRT-PCR mRNA analysis of Jagged2 following the same methods described in H (** P < 0.01).

Article Snippet: JAG2 (cat#TL303860) human 4-unique shRNA constructs in lentiviral GFP vector were purchased from Origene (OriGene Technologies, USA).

Techniques: Injection, Staining, Comparison, RNA Expression, In Vivo, Immunofluorescence, Western Blot, Quantitative RT-PCR, Cell Culture, Ex Vivo, Proliferation Assay, Labeling, FACS

Journal: Cell Death & Disease

Article Title: Ovarian tumor cell-derived JAGGED2 promotes omental metastasis through stimulating the Notch signaling pathway in the mesothelial cells

doi: 10.1038/s41419-024-06512-0

Figure Lengend Snippet: A Heat map showing the qRT-PCR gene expression of the Notch pathway ligands and downstream targets in four ovarian cancer cell lines. B qRT-PCR analysis of the Jagged2 gene expression in ovarian cancer cell lines with distinct metastatic abilities. C Heat map showing the microarray data analysis of the Jagged2 mRNA expression in ovarian cancer cell lines with metastatic ability. D – F Kaplan-Meier progression-free survival curves of ovarian cancer patients from Gentric (GSE26193) , Denkert (GSE14764) , and TCGA data sets representing high and low expression of Jagged2. G Western blot analysis of the Jagged2 protein in control and Jagged2 knockdown (KD) in OVCAR3 and SKOV3-ip cells. H (Top) Representative images of tumor nodules in mouse metastatic omentum (right) and tumors developed in the primary ovary (left). (Bottom) quantification of tumor area from each group. Scale bar 100 μm. *** P < 0.001. I–L Kaplan-Meier survival and omental metastasis- free curves of mice injected with control or Jagged2 knockdown (Jag2KD) OVCAR3 and SKOV3-ip cells (n = 5 mice per/group). M (Left panel) Representative immunohistochemical images of Ki-67 and H & E histological images of primary omentum from representative mice for each experimental group. (Right panel) quantification of Ki-67 -positive cells in the Jag2KD cells compared with the control group. Scale bar 20 μm. P = 0.12 (OVACR3 cells) and 0.44 (SKOV3-ip cells). Data in the figure represent average and +/-SEM; P -values were determined using the Student’s t -test unless otherwise indicated.

Article Snippet: JAG2 (cat#TL303860) human 4-unique shRNA constructs in lentiviral GFP vector were purchased from Origene (OriGene Technologies, USA).

Techniques: Quantitative RT-PCR, Gene Expression, Microarray, Expressing, Western Blot, Control, Knockdown, Injection, Immunohistochemical staining

Journal: Cell Death & Disease

Article Title: Ovarian tumor cell-derived JAGGED2 promotes omental metastasis through stimulating the Notch signaling pathway in the mesothelial cells

doi: 10.1038/s41419-024-06512-0

Figure Lengend Snippet: A Western blot analysis showing Jagged2 protein expression in control and Jag2OE OV2774 cell line. B Mice inoculated with control and Jag2OE cells showed the absence ( n = 5) and presence ( n = 5) of omental tumor nodules with histological and Jagged2 immunofluorescence. Magnification of images are taken at 40x (scale bar = 200 μm). C Quantification of tumor area in the omentum from each mice group ( P = 0 .0019). Error bar represent Mean +/- SD; *** P < 0.001. D Quantification of tumor weight (in grams) from each mice group from the day of inoculation (0 days) up to day 25. Error bar represent Mean +/- SD; ns - not significant; * P < 0.05; ** P < 0.01 and *** P < 0.001, respectively. E Kaplan-Meier omental metastasis-free survival curve of mice inoculated with control ( n = 5) or Jag2OE ( n = 5) (Log-rank P < 0.012). F Representative images of freshly resected human omentum showing absence (no omental metastasis; n = 4) and presence (omental metastasis; n = 4) of omental tumors with histological analysis of both H & E and Jagged2 immunofluorescence. Scale bar 100 μm. G Immunofluorescence staining of Ki-67 from omental metastatic tumors from each group (left panel). The right panel illustrates the quantification of the percent of Ki-67 -positive tumor cells. For the quantification analysis, 10 distinct regions were randomly selected from each group. * P < 0.05. H (Left panel) Representative images of invaded cells and (right panel) quantification of cells invasive capability of control and Jag2OE cells using two-chamber transwell Matrigel invasion assay. ** P < 0.01. Scale bar 100 μm, I qRT-PCR mRNA expression analysis of the Notch target genes Hes1 (** P < 0.01), Hey1 (*** P < 0.001), and the Notch receptor Jagged2 (** P < 0.01) in control and Jag2OE OV2774 mice omental metastatic site. Data in the figure represent average and +/-SEM; P -values were determined using the Student’s t -test unless otherwise indicated.

Article Snippet: JAG2 (cat#TL303860) human 4-unique shRNA constructs in lentiviral GFP vector were purchased from Origene (OriGene Technologies, USA).

Techniques: Western Blot, Expressing, Control, Immunofluorescence, Staining, Invasion Assay, Quantitative RT-PCR

Journal: Cell Death & Disease

Article Title: Ovarian tumor cell-derived JAGGED2 promotes omental metastasis through stimulating the Notch signaling pathway in the mesothelial cells

doi: 10.1038/s41419-024-06512-0

Figure Lengend Snippet: A Gene-set enrichment analysis (GSEA) of the TGF-β-responsive genes set in a ranked list of differentially expressed genes in primary ovary tumors versus omental metastatic tumor cells (GSE2109; P = 0.037). The bottom panel shows a corresponding heat map of core TGF-β gene sets with elevated expression in two groups. B Jagged2 mRNA expression in response to TGF-β treatment in ovarian cancer cell lines. ** P < 0.01, *** P < 0.001. C Jagged2 mRNA expression in SKOV3-ip cells treated with either DMSO or TGF-β-receptor inhibitor (EMD616451) for 24 hours. *** P < 0.001. D Cell proliferation assay of SKOV3-ip cells treated with either DMSO or TGF-β-receptor inhibitor (EMD616451) for the indicated time. * P < 0.05, *** P < 0.001. E Jagged2 mRNA expression in ovarian cancer cells treated with either DMSO or Smad3 inhibitor (SIS3) for 24 hours. *** P < 0.001. F Number of invaded cells in the indicated cells with altered expression of Jagged2 and Smad3. ** P < 0.01, *** P < 0.001. G Representative images of the omental region in mice from experimental groups on day 10. (left) Quantification of tumor numbers in each group of experimental mice. Data in the figure represent average +/- SEM, SD. ** P < 0.01, *** P < 0.001. H Western blot analysis showing Jagged2, Smad3, and phospho-Smad3 expression in the indicated cells with altered Jagged2 and Smad3. I Western blot analysis of Jagged2, phospho-Smad3, and Smad3 protein levels in the control or Smad3 knockdown in Jag2OE cells with or without stimulation of TGF-β. J Western blot analysis showing Jagged2 protein expression in the control and Jag2KD SKOV3-ip cells with or without TGF-β treatment. Data in the figure represent average and +/-SEM; P -values were determined using the Student’s t -test unless otherwise indicated.

Article Snippet: JAG2 (cat#TL303860) human 4-unique shRNA constructs in lentiviral GFP vector were purchased from Origene (OriGene Technologies, USA).

Techniques: Expressing, Proliferation Assay, Western Blot, Control, Knockdown

Journal: Cell Death & Disease

Article Title: Ovarian tumor cell-derived JAGGED2 promotes omental metastasis through stimulating the Notch signaling pathway in the mesothelial cells

doi: 10.1038/s41419-024-06512-0

Figure Lengend Snippet: A Schematic diagram of a co-culture model between Jag2OE tumor cells and human primary mesothelial cells transfected with a Notch reporter. B Flow cytometry cells separation of mesothelial cells (P2) from GFP+ Jag2OE cells (P3). After flow cytometry cell separation, the bottom panel shows the quantification of the Jagged2 mRNA expression control and sorted co-culture cells from the indicated group (*** P < 0.001). C Co-culture between control or Jag2OE tumor cells and mesothelial cells transfected with a Notch reporter and treated with DMSO or MRK-003 (1 and 5 μM). D qRT-PCR assessment of the mRNA levels of the indicated Notch target genes, TGF-β1 and fibronectin 1 (FN1) in mesothelial cells separated by FACS from co-culture in each experimental group. * P < 0.05, ** P < 0.01, and *** P < 0.001. E qRT-PCR analysis of Jagged2 mRNA expression in primary human mesothelial cells with or without a conditioned medium (CM) from Jog2OE cells for the indicated time periods. * P < 0.05. F Representative images of co-cultures of Jag2OE and mesothelial cells from each experimental group (DMSO or MRK-003 [5 μM]). Scale bar, 200 μm. G Quantifying tumor cell proliferation of control and Jag2OE cells after co-culture with mesothelial cells from each experimental group by luciferase assay. ** P < 0.01, *** P < 0.001. H Quantification of sphere growth efficiency of control and Jag2OE after co-cultures of each experimental treatment group. ** P < 0.01, *** P < 0.001. I Quantification of tumor cell proliferation cultured alone (no co-culture) from each experimental group. Data in the figure represent average and +/-SEM; P -values were determined using the Student’s t -test unless otherwise indicated. ns = not significant. All experiments were run in triplicates.

Article Snippet: JAG2 (cat#TL303860) human 4-unique shRNA constructs in lentiviral GFP vector were purchased from Origene (OriGene Technologies, USA).

Techniques: Co-Culture Assay, Transfection, Flow Cytometry, Expressing, Control, Quantitative RT-PCR, Luciferase, Cell Culture

Journal: Cell Death & Disease

Article Title: Ovarian tumor cell-derived JAGGED2 promotes omental metastasis through stimulating the Notch signaling pathway in the mesothelial cells

doi: 10.1038/s41419-024-06512-0

Figure Lengend Snippet: A Jagged2 expression was examined by fluorescent-activated cell sorting (FACS) in tissues from omentum ( n = 4) sampled from patients treated for benign disease, OvCa primary tumors ( n = 4), and omental metastasis ( n = 4) collected from patients with serous OvCa. Metastatic tumors in the omentum ( n = 4) had a higher percentage of Jagged2+ cells compared with patients who were either primary tumors or benign omentum ( n = 4). ** P < 0.01, *** P < 0.001 unpaired two-sided t -test. B Spheroids formation assay comparing cultured omental metastatic (Jag2High) and non-metastatic omentun (Jag2Low) cells. Cells were seeded in ultra-low adherence 96-well plates, and the formation of spheroids was assessed with a wide-filed microscope. (Mean SEM + /-). Scale bar 200 μm. Jagged2 protein immunofluorescently stained with Jagged2 specific primary antibody in cultured spheroids. (Mean SEM + /-). *** P < 0.001, unpaired two-sided t -test. C (Left)Representative images of tumor localization in mouse omentaum at day 10 after injection of control and Jag2OE cells. (Right) Analysis of tumor burden in omentum at day 10 after injection. Data are presented as mean +/-SD ( n = 3) and a statistically significant difference was calculated using the Man-Whitney U test, *** P < 0.001. D Sphere-formation assay of SKOV3-ip and Jag2OE cells after mesothelial cell exposure. Representative sphere images and quantification of sphere numbers fold increase is shown ( n = 3). Scale bar 200 μm. A statistically significant difference was calculated using the Man-Whitney U test, *** P < 0.001. E In vivo limiting dilution assay showing tumor formation rate of Jag2OE cells co-injected with mesothelial cells ( n = 3 mouse/group). F Number of spheres and sphere diameter ( n = 3) in the indicated treatment group. ** P < 0.01, *** P < 0.001. G qRT-PCR analysis showing relative mRNA expression of the stemness markers, Sox2, Nanog, Oct3/4 in the indicated treatment group. One-way ANOVA test. * P < 0.05, ** P < 0.01, *** P < 0.001. H ALDH1L1 mRNA in Jag2OE cells after coculture with mesothelial cells and in the indicated treatment groups as normalized to GAPDH mRNA ( n = 3). * P < 0.05, ** P < 0.01. I (right) Schematic presentation of the drug response assay designed to assess the proportion of apoptotic cells among the co-cultured OvCa and mesothelial cells. (left) GFP-labeled Jag2OE cells isolated from mesothelial cells were stained with Annexin-V and 7-AAD and the proportion of Annexin-V positive cells was determined by flow cytometry. J The percentage of Annexin-V-7AAD positive cells were presented from paired samples ( n = 8, P = 0.0078). p -values were analyzed based on Wilcoxon test. Data in the figure represent average and +/-SEM; P -values were determined using the Student’s t -test unless otherwise indicated.

Article Snippet: JAG2 (cat#TL303860) human 4-unique shRNA constructs in lentiviral GFP vector were purchased from Origene (OriGene Technologies, USA).

Techniques: Expressing, FACS, Tube Formation Assay, Cell Culture, Microscopy, Staining, Injection, Control, In Vivo, Limiting Dilution Assay, Quantitative RT-PCR, Labeling, Isolation, Flow Cytometry

Journal: Cell Death & Disease

Article Title: Ovarian tumor cell-derived JAGGED2 promotes omental metastasis through stimulating the Notch signaling pathway in the mesothelial cells

doi: 10.1038/s41419-024-06512-0

Figure Lengend Snippet: A A List of genes with an expression fold change between pleural malignant and peritoneal malignant mesothelial cells of more than 2-fold from the public dataset microarray GSE63966. B qRT-PCR mRNA analysis of the Notch target genes, and CTGF and FN1 from mesothelial cells, omental metastatic tumor cells, and primary ovary tumor cells resected from the patient. C (Left) Schematic model of the co-culture system of mesothelial and Jag2OE cells. (Right) qRT-PCR mRNA expression of the indicated genes in control and Jag2OE tumor cells cocultured with mesothelial cells. * P < 0.05, ** P < 0.01, *** P < 0.001. D Heat map showing qRT-PCR mRNA expression levels of the indicated genes from mesothelial cells that were FACS separated from cocultures of each experimental/treatment group. E qRT-PCR analysis of Hes1 expression in mesothelial cells treated with scrambled or Hes1 siRNA and cultured in 24 well plates coated with either Fc or control or recombinant Jagged2 protein ( n = 3). Data represent average +/- SD. ** P < 0.01, *** P < 0.001. F Quantification of cell proliferation in mesothelial cells treated with control or Hes1 siRNA and cultured in 24 well plates coated with either Fc or control or recombinant Jagged2 protein by luciferase assay ( n = 3). ** P < 0.01, *** P < 0.001. G Quantification of IL-6 levels in the conditioned media of control or Jag2OE tumor cells cultured alone or cocultured with mesothelial cells in the presence of DMSO, MRK-003 (1μM) by ELISA ( n = 3). ** P < 0.01, **** P < 0.001. H Quantification of IL-6 levels in the conditioned media of the indicated tumor cells co-cultured with mesothelial cells after treatment with Hes1 siRNA by ELISA. *** P < 0.001. I Cell proliferation of the indicated tumor cells co-cultured with mesothelial cells from each experimental group by luciferase assay. Data represent average +/-SD, ** P < 0.01, *** P < 0.001. J Cell proliferation of the indicated tumor cells cocultured with mesothelial cells after treatment with Hes1 siRNA by luciferase assay. ** P < 0.01, *** P < 0.001. K Quantification of sphere formation capacity of the indicated tumor cells cocultured with mesothelial cells after treatment with Hes1 siRNA. ** P < 0.01, *** P < 0.001. L Quantification of sphere formation capacity of indicated tumor cells cocultured with mesothelial cells after treatment with 1 μM MRK-003. ** P < 0.01, *** P < 0.001. M Cell proliferation of indicated tumor cells cocultured with mesothelial cells and treatment with either IgG or 5.0 μg/mL of the anti-IL-6 antibody by luciferase assay. ** P < 0.01, *** P < 0.001. N Cell proliferation of indicated tumor cells cocultured with mesothelial cells and treatment with either PBS, 5.0 μg/mL, or 10.0 μg/mL of anti-IL6 by luciferase assay. * P < 0.05, *** P < 0.001. Data in the figure represent average and +/-SEM; P -values were determined using the Student’s t -test unless otherwise indicated. All experiments were run in triplicates.

Article Snippet: JAG2 (cat#TL303860) human 4-unique shRNA constructs in lentiviral GFP vector were purchased from Origene (OriGene Technologies, USA).

Techniques: Expressing, Microarray, Quantitative RT-PCR, Co-Culture Assay, Control, Cell Culture, Recombinant, Luciferase, Enzyme-linked Immunosorbent Assay

Journal: Cell Death & Disease

Article Title: Ovarian tumor cell-derived JAGGED2 promotes omental metastasis through stimulating the Notch signaling pathway in the mesothelial cells

doi: 10.1038/s41419-024-06512-0

Figure Lengend Snippet: A , B OvCa cells were treated with vehicle and MRK-003 (5 μM), followed by the addition of fluorescently labeled SKOV3-ip and OVCAR3 cells and later detected by fluorescent reader. ** P < 0.01, *** P < 0.001. C The experimental model of vehicle or MRK-003 (5 μM) treated and fluorescently labeled OvCa cells seeded in a piece of human omentum (72 hours). D–E Jagged2 inhibition by MRK-003 as described in ( A and B ). After scraping off the omentum surface cells of the omentum, Jagged2 ( D ) and CD44 ( E ) were quantified using qRT-PCR. * P < 0.05, *** P < 0.001. F Quantification of the number of cells after scrapping from the omentum. * P < 0.05, ** P < 0.01. G - H qRT-PCR mRNA analysis of the Notch target genes and IL-6 from scraped-off cells from the omentum. * P < 0.05, ** P < 0.01, *** P < 0.001. I Kaplan-Meier omental metastasis-free survival curve of mice from each experimental group. (Log-rank P = 0.018). J Representative images of tumor metastasis to omentum (top; highlighted with white circles) and primary ovary site (bottom) in female mice injected with SKOV3-ip cells and treated with vehicle or MRK-003. K–N Omental tumor weight ( K ), omental tumor number ( L ), ascites volume ( M ), and omental weight ( N ) at the endpoint of mice intraperitoneal inoculation. P = 0.006 and 0.009; * P < 0.05, *** P < 0.001. O qRT-PCR analysis of the Notch target genes and IL-6 in the tumor-stromal compartment of omental metastasis from vehicle or MRK-003 treated mice. * P < 0.05, ** P < 0.01, *** P < 0.001. Data in the figure represent average and +/-SEM; P values were determined using the Student’s t -test unless otherwise indicated. All experiments were run in triplicates.

Article Snippet: JAG2 (cat#TL303860) human 4-unique shRNA constructs in lentiviral GFP vector were purchased from Origene (OriGene Technologies, USA).

Techniques: Labeling, Inhibition, Quantitative RT-PCR, Injection

Journal: Cell Death & Disease

Article Title: Ovarian tumor cell-derived JAGGED2 promotes omental metastasis through stimulating the Notch signaling pathway in the mesothelial cells

doi: 10.1038/s41419-024-06512-0

Figure Lengend Snippet: A Schematic diagram of i.p. cell injection and treatment schedules. B Images of representative mice in each experimental group on day 40 after peritoneal injection. C Kaplan-Meier omental metastasis-free survival curve of mice from each experimental group. Log-rank P = 0.0032. D–F Omental tumor weight ( D ), omental tumor number ( E ), and ascites volume ( F ) of mice from each experimental group (mean +/- SEM, n = 5 for each experiment, ** P < 0.01, *** P < 0.001, Students t - test). G A graphical presentation of tumor-mesothelial cell cross-talk of Jagged2-expressing ovarian tumor cells with the omental microenvironment. Data in the figures represent average and +/-SEM; P -values were determined using the Student’s t -test unless otherwise indicated. All experiments were run in triplicates.

Article Snippet: JAG2 (cat#TL303860) human 4-unique shRNA constructs in lentiviral GFP vector were purchased from Origene (OriGene Technologies, USA).

Techniques: Injection, Expressing